Success Metrics

Clinical Success Rate
75.0%

Based on 3 completed trials

Completion Rate
75%(3/4)
Active Trials
0(0%)
Results Posted
133%(4 trials)
Terminated
1(25%)

Phase Distribution

Ph phase_4
1
25%
Ph phase_2
2
50%
Ph phase_3
1
25%

Phase Distribution

0

Early Stage

2

Mid Stage

2

Late Stage

Phase Distribution4 total trials
Phase 2Efficacy & side effects
2(50.0%)
Phase 3Large-scale testing
1(25.0%)
Phase 4Post-market surveillance
1(25.0%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

75.0%

3 of 4 finished

Non-Completion Rate

25.0%

1 ended early

Currently Active

0

trials recruiting

Total Trials

4

all time

Status Distribution
Completed(3)
Terminated(1)

Detailed Status

Completed3
Terminated1

Development Timeline

Analytics

Development Status

Total Trials
4
Active
0
Success Rate
75.0%
Most Advanced
Phase 4

Trials by Phase

Phase 22 (50.0%)
Phase 31 (25.0%)
Phase 41 (25.0%)

Trials by Status

terminated125%
completed375%

Recent Activity

0 active trials
Showing 4 of 4
completedphase_2

A Study to Find the Dose and Assess the Immune Response and Safety of a Vaccine Against Influenza in Healthy Younger and Older Adults

NCT06431607
completedphase_3

A Study to Evaluate the Safety and Immune Response of mRNA-1345, a Vaccine Targeting Respiratory Syncytial Virus (RSV), When Co-administered With a Fluzone HD, in Adults ≥65 Years of Age

NCT06060457
terminatedphase_2

Phase 2 Dose and Formulation Confirmation of Quad-NIV in Older Adults

NCT03658629
completedphase_4

Comparison of Three Licensed Influenza Vaccines

NCT03068949

Clinical Trials (4)

Showing 4 of 4 trials
NCT06431607Phase 2

A Study to Find the Dose and Assess the Immune Response and Safety of a Vaccine Against Influenza in Healthy Younger and Older Adults

Completed
NCT06060457Phase 3

A Study to Evaluate the Safety and Immune Response of mRNA-1345, a Vaccine Targeting Respiratory Syncytial Virus (RSV), When Co-administered With a Fluzone HD, in Adults ≥65 Years of Age

Completed
NCT03658629Phase 2

Phase 2 Dose and Formulation Confirmation of Quad-NIV in Older Adults

Terminated
NCT03068949Phase 4

Comparison of Three Licensed Influenza Vaccines

Completed

All 4 trials loaded

Drug Details

Intervention Type
COMBINATION PRODUCT
Total Trials
4